| Date | Title | Description |
| 25.10.2024 | Business | Boulder biotech entrepreneur seeks sales record with $15M listing | Kevin Ness is the former CEO of Inscripta, a life science technology company.
Subscribe to continue reading this article. Already subscribed? To login in, click here.
Originally Published: October 25, 2024 at 3:00 p.m. |
| 22.10.2024 | Cloud-Connected Bioreactors: Optimizing Synthetic Biology Scale-Up, Upcoming Webinar Hosted by Xtalks | www.culturebiosciences.com
In this free webinar, learn how cloud-connected bioreactors can accelerate the scale-up process for biomanufacturing. Attendees will gain insights into troubleshooting methods to overcome scale-up challenges. The ... |
| 01.04.2024 | Впервые в мире почку свиньи изменили генетически и пересадили человеку. Теперь их можно массово пересаживать... | Хирурги из США провели человеку трансплантацию почки, полученной из генетически модифицированной свиньи. СМИ сообщают, что данная операция является прорывом в области ксенотрансплантации, когда органы, клетки или ткани пересаживаются из одн... |
| 11.04.2023 | Exclusive: The University of California has invested billions in venture capital firms since 2000 and it has lost hundreds of millions so far. Here's why. | Jagdeep Singh Bachher is chief investment officer at UC Investments. L'Attitude This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Insider obtained UC Investments' returns through... |
| 05.05.2022 | Data Snapshot: Food security & sustainability drove $2.6b in funding for Ag Biotech in 2021 | Data Snapshot is a regular AFN feature analyzing agrifoodtech market investment data provided by our parent company, AgFunder.
Click here for more research from AgFunder and sign up to our newsletters to receive alerts about new research re... |
| 20.08.2021 | The Andersons, Inc. : Announces $100 Million Share Repurchase Program | MAUMEE, Ohio, Aug. 20, 2021 /PRNewswire/ -- The Andersons, Inc. (Nasdaq: ANDE) announces its Board of Directors have authorized a share repurchase program of up to $100 million of outstanding company common stock.
"A continued focus on... |
| 05.04.2021 | Inscripta closes $150M VC round, scores first commercial buyer of CRISPR gene editing platform | Inscripta just got another step closer to achieving its mission of bringing CRISPR gene editing technology to the scientific masses.
The genomic engineering company, a member of Fierce Medtech’s 2019 Fierce 15, recently closed a series E f... |
| 05.04.2021 | Inscripta Closes $150M Series E Financing | Inscripta, Inc., a Boulder, CO-based digital genome engineering company, closed a $150m Series E financing.
The round was led by Fidelity Management & Research Company LLC and funds and accounts advised by T. Rowe Price Associates, Inc.... |
| 05.04.2021 | Inscripta Announces the First Commercial Shipment of Its Onyx™ Digital Genome Engineering Platform and Closes $150 Million in New Financing | Inscripta, Inc., the digital genome engineering company, today announced the first commercial shipment of its Onyx™ platform and the closing of a $150 million Series E financing round led by Fidelity Management & Research Company LLC an... |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages
The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |
| 30.11.2020 | Boulder-based genomic engineering company Inscripta raises $58M | Inscripta Inc. has raised $58 million in its latest round of fundraising as it continues on the path of commercializing its gene-editing platform.
The Boulder-based Inscripta raised the funds from seven investors, including one who purchase... |
| 10.12.2019 | Inscripta Raises $125M in Series D Financing to Accelerate Commercialization of Revolutionary Digital Genome Engineering Platform | BOULDER, Colo.--(BUSINESS WIRE)--Inscripta, Inc., today announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Pala... |
| 10.12.2019 | $125 million for Inscripta may usher in the next wave of genetic engineering | In these waning days of the second decade of the twenty-first century, technologists and investors are beginning to lay the foundations for new, truly transformational technologies that have the potential to reshape entire industries and re... |
| 10.12.2019 | Inscripta Secures $125M in Series D Financing | Inscripta, Inc., a Boulder, Colo.-based provider of an automated benchtop instrument for genome-scale engineering, raised $125m in Series D financing.
The round, which brought the total amount raised to date to $259.5m, was led by Paladin C... |
| 10.12.2019 | Inscripta Raises $125M in Series D Financing | New funding brings total amount raised to $259.5M and will be used to accelerate commercialization of revolutionary Digital Genome Engineering Platform. |
| 12.04.2019 | Boulder-Based Gene Editing Company Inscripta Secures $20 Million | Boulder, Colorado-based gene editing company Inscripta announced it has increased its previously announced Series C funding round with $20 million from existing investors. This new funding round adds to the $85.5 million that the company an... |
| 05.04.2019 | Investors Share Their Most Cringe-Worthy Misses: Term Sheet for Friday, April 5 | BIG REGRETS
On the eve of Lyft’s IPO, Twitter lit up with investors lamenting their failure to invest during the early days of the ride-hailing company.
Paid Content You can't secure what you can't see From ExtraHop
Upfront Ventures’ Mark S... |
| 05.04.2019 |
Inscripta, With Offices In San Diego, Finds $20M For Series C Funding
| Gene editing technology developer Inscripta, which has one of its offices in San Diego, saidt his week that has added another $20M in funding to its Series C round, bringing the round to a total of $105.5M. According to Inscripta, the new f... |
| 04.04.2019 | Inscripta Expands Series C Financing Round to $105.5M | NEW YORK (GenomeWeb) – Gene editing technology company Inscripta said today that it that its existing investors have agreed to contribute an additional $20 million to its previously announced Series C funding round, bringing the total raise... |
| 04.04.2019 | Inscripta Completes $20M Expansion of Series C Financing, Increasing Total Round to $105.5M | Continued support of existing investors will fund commercialization efforts, product launch later this year. |
| 04.04.2019 | Inscripta Completes $20M Expansion of Series C Financing | Inscripta, a Boulder, CO-based gene editing technology company, increased its previously announced Series C financing with an additional $20m.
The new funding, which adds to the $85.5m financing Inscripta announced in 2018, bringing the tot... |
| 15.09.2018 | 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. But every day some of the... |
| 05.09.2018 | Inscripta Acquires Former Illumina Team via Solana Biosciences to Commercialize Gene Editing Tools | Inscripta (formerly Muse Bio), a gene-editing startup that earlier this year raised a $55 million Series C funding round, has acquired Solana Biosciences, a life sciences company offering consulting, raw material manufacturing, and commerci... |
| 10.05.2018 | Should You Be Using CRISPR for Your Ag Business? | *Updated reference to Pairwise with correction regarding agreement with Monsanto*
Editor’s Note: Vonnie Estes was the 2017 recipient of Rosalind Franklin award for leadership in Biotechnology. She is an agtech innovation consultant with a p... |
| 28.02.2018 | Inscripta Completes $55.5M Series C Funding | Inscripta, a Boulder, CO and Pleasanton, CA-based gene-editing technology company, completed a $55.5m Series C funding.
Backers included Mérieux Développement and Paladin Capital Group and existing investors Venrock, Foresite, Spruce, and N... |
| 28.02.2018 | Startup making Cas9 proxy for gene editing gets $55M to develop tools/software | Boulder-based startup Inscripta — which you might remember as the company that discovered a new CRISPR enzyme… and then gave it away for free — just landed $55.5 million in a Series C round.
Inscripta made headlines last De... |
| 28.02.2018 | CRISPR Startup Inscripta Raises $55.5m Series C to Democratize Gene-Editing | Inscripta (formerly Muse Bio) has raised a $55.5 million Series C round led by healthcare investor Mérieux Développement and Washington, DC-based private equity firm Paladin Capital Group. Existing investors Venrock, Foresite, MLS Capital, ... |
| 28.02.2018 | Inscripta Raises $55.5 Million to Advance Gene-Editing Technology | Inscripta, a leading gene-editing technology company, today announced that it has closed a $55.5 million Series C funding round led by Mérieux Développement and Paladin Capital Group. Additional participants include all existing Inscripta i... |
| - | Inscripta | “Our revolutionary digital genome engineering tools transform how we face complex global challenges and yield solutions that benefit all.” |
